Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

PaperCitations, authors & open-access status

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 284 citations, 2021 year and hybrid oa status.

284
Citations
2021
Year
hybrid
OA Status

Related on ScholarIQ

Weidong Li
Author
Journal of Thoracic Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
Monoclonal and Polyclonal Antibodies Research
Topic
Esophageal Cancer Research and Treatment
Topic
470M+ articles · free account